The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00280085
Recruitment Status : Terminated (Explanation provided in detailed descriptiong section of record.)
First Posted : January 20, 2006
Last Update Posted : August 7, 2009
Yale University
Information provided by:

January 18, 2006
January 20, 2006
August 7, 2009
December 2005
Not Provided
Pancreatic perfusion
Pancreatic perfusion Information omitted due to commercial sensitivity
Complete list of historical versions of study NCT00280085 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.
Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging
Assess pancreatic beta cell function using MR imaging.
The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.
Not Applicable
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Diabetes Mellitus
  • Procedure: MR imaging
  • Procedure: Glucose clamp
  • Drug: Arginine
    Other Name: R-Gene 10
Not Provided
Hirshberg B, Qiu M, Cali AM, Sherwin R, Constable T, Calle RA, Tal MG. Pancreatic perfusion of healthy individuals and type 1 diabetic patients as assessed by magnetic resonance perfusion imaging. Diabetologia. 2009 Aug;52(8):1561-5. doi: 10.1007/s00125-009-1406-8. Epub 2009 Jun 3.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2007
Not Provided

Inclusion Criteria:

  • Normal Volunteers
  • T1DM and T2DM subjects

Exclusion Criteria:

  • Concomitant severe conditions
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Yale University
Study Director: Pfizer Call Center Pfizer
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP